Alastair C. Mcgregor
London, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 39 publications
Infection-embedded penicillin allergy de-labelling delivers immediate antimicrobial stewardship gains in patients with active infection.
Journal: JAC-antimicrobial resistance
Published: July 10, 2026
ChAdOx1 nCoV-19 coronavirus vaccine: Long-term safety and immunological responses.
Journal: Vaccine
Published: March 19, 2026
Anti-MDA5-associated rapidly progressive-ILD-the intersection of hyperinflammation and fibrosis.
Journal: The Lancet. Rheumatology
Published: January 24, 2026
Unusually Extensive Furuncular Myiasis in a Returning Traveller from Rural Ethiopia Complicated by Streptococcus Pyogenes Secondary Infection Following Albendazole Therapy.
Journal: Reports (MDPI)
Published: December 22, 2025
Heterologous COVID-19 vaccine schedule with protein-based prime (NVX-CoV2373) and mRNA boost (BNT162b2) induces strong humoral responses: Results from COV-BOOST trial.
Journal: The Journal of infection
Published: March 11, 2025
Corrigendum to "Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial" [J Infect 84(6) (2022) 795-813, 5511].
Journal: The Journal of infection
Published: April 13, 2023
Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial.
Journal: The Journal of infection
Published: January 11, 2023
A Painful Breast Mass.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: December 19, 2022
Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial.
Journal: The Lancet. Infectious diseases
Published: April 12, 2022
Cohorting inpatients with Omicron and Delta variants of Sars-CoV-2 does not increase rates of mixed infection.
Journal: The Journal of infection
Published: March 29, 2022
Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial.
Journal: The Journal of infection
Published: March 17, 2022
Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial.
Journal: Lancet (London, England)
Published: November 04, 2021
Last Updated: 09/26/2026